Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

AVIRAtea Pharmaceuticals, Inc.

Nasdaq · CIK 0001593899
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts234

Identity from submissions API

NameAtea Pharmaceuticals, Inc.
CIK0001593899
TickersAVIR
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN460574869
LEI—
Fiscal year end1231
State of incorporationMA MA
Phone(857) 284-8891
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
225 FRANKLIN STREET
SUITE 2100
BOSTON
MA
02110
MA
Mailing address
225 FRANKLIN STREET
SUITE 2100
BOSTON
MA
02110
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

326 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-19 4 4 0001193125-26-469038 13850
2026-11-19 4 4 0001193125-26-469037 5150
2026-11-19 144 xsl144X01/primary_doc.xml 0001950047-26-011363 001-39661 261575466 33 5367
2026-11-19 144 xsl144X01/primary_doc.xml 0001950047-26-011348 001-39661 261575168 33 6775
2026-11-18 4 4 0001193125-26-467490 19074
2026-11-18 144 xsl144X01/primary_doc.xml 0001950047-26-011332 001-39661 261571391 33 6082
2026-11-17 144 xsl144X01/primary_doc.xml 0001950047-26-011253 001-39661 261566813 33 5381
2026-11-17 144 xsl144X01/primary_doc.xml 0001950047-26-011221 001-39661 261566427 33 4666
2026-11-16 144 xsl144X01/primary_doc.xml 0001950047-26-011130 001-39661 261560975 33 4683
2026-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-460848 005-91836 261553493 34 9098
2026-11-09 10-Q 10-Q 0001193125-26-453807 001-39661 261536858 34 9807494 1 1
2026-11-09 8-K 8-K 2.02,9.01 0001193125-26-453636 001-39661 261536208 34 223541 1 1
2026-11-09 8-K 8-K 1.01,2.03,9.01 0001193125-26-452659 001-39661 261533817 34 746604 1 1
2026-10-06 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001214659-26-012604 005-91836 261445088 34 27348
2026-08-12 10-Q 10-Q 0001193125-26-347021 001-39661 261268263 34 9153477 1 1
2026-08-12 8-K 8-K 2.02,9.01 0001193125-26-346888 001-39661 261267680 34 226137 1 1
2026-06-23 4 4 0001193125-26-279728 11468
2026-06-23 4 4 0001193125-26-279726 11484
2026-06-23 4 4 0001193125-26-279723 7945
2026-06-23 4 4 0001193125-26-279721 11600
2026-06-23 4 4 0001193125-26-279719 11483
2026-06-23 4 4 0001193125-26-279718 11477
2026-06-23 4 4 0001193125-26-279720 11491
2026-06-23 4 4 0001193125-26-279717 8043
2026-06-22 8-K 8-K 5.07 0001193125-26-277639 001-39661 261107844 34 147770 1 1
2026-05-21 4/A 4/A 0001193125-26-235039 5469
2026-05-20 4 4 0001193125-26-232612 5057
2026-05-12 10-Q 10-Q 0001193125-26-219678 001-39661 26969436 34 8123621 1 1
2026-05-12 8-K 8-K 2.02,9.01 0001193125-26-219507 001-39661 26968836 34 208545 1 1
2026-05-06 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-001112 005-91836 26946575 34 11338
2026-04-27 DEFA14A DEFA14A 0001193125-26-182340 001-39661 26901832 34 1909369
2026-04-27 DEF 14A DEF 14A 0001193125-26-182293 001-39661 26901701 34 15543241 1 1
2026-03-26 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-000786 005-91836 26798349 34 7119
2026-03-13 4 4 0001193125-26-106547 6614
2026-03-05 10-K 10-K 0001193125-26-094159 001-39661 26727010 34 16635234 1 1
2026-03-05 8-K 8-K 2.02,9.01 0001193125-26-093961 001-39661 26726215 34 224641 1 1
2026-02-09 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001373604-26-000010 005-91836 26610869 34 7944
2026-02-03 4 4 0001193125-26-036281 12674
2026-02-03 4 4 0001193125-26-036272 13409
2026-02-03 4 4 0001193125-26-036270 12862
2026-02-03 4 4 0001193125-26-036269 12902
2026-02-03 4 4 0001193125-26-036268 14888
2026-02-03 4 4 0001193125-26-036261 12660
2026-01-08 8-K 8-K 2.02,9.01 0001193125-26-007081 001-39661 26517656 34 183426 1 1
2025-12-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-002957 005-91836 251552354 34 11622
2025-11-12 10-Q 10-Q 0001193125-25-277815 001-39661 251473742 34 9420886 1 1
2025-11-12 8-K 8-K 2.02,9.01 0001193125-25-277627 001-39661 251472973 34 225162 1 1
2025-08-07 S-8 S-8 0001193125-25-175553 333-289387 251195159 33 195104 1 1
2025-08-07 10-Q 10-Q 0000950170-25-105123 001-39661 251194773 34 9084969 1 1
2025-08-07 8-K 8-K 2.02,9.01 0001193125-25-175433 001-39661 251194098 34 214376 1 1
2025-08-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-001974 005-91836 251188276 34 11051
2025-06-24 4 4 0000950170-25-089607 11401
2025-06-24 4 4 0000950170-25-089609 11409
2025-06-24 4 4 0000950170-25-089606 11382
2025-06-24 4 4 0000950170-25-089605 11375
2025-06-24 4 4 0000950170-25-089608 11396
2025-06-24 4 4 0000950170-25-089604 11388
2025-06-24 4 4 0000950170-25-089603 5223
2025-06-24 3 3 0000950170-25-089596 17974
2025-06-20 8-K 8-K 5.07 0001193125-25-143750 001-39661 251062309 34 147657 1 1
2025-05-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-071707 005-91836 25947589 34 8959
2025-05-12 10-Q 10-Q 0000950170-25-069367 001-39661 25935598 34 8774379 1 1
2025-05-12 8-K 8-K 2.02,9.01 0001193125-25-117809 001-39661 25935201 34 215575 1 1
2025-04-29 DEF 14A DEF 14A 0001193125-25-104019 001-39661 25888978 34 8886053 1 1
2025-04-23 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-001472 005-91836 25863202 34 10854
2025-04-17 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000921895-25-001112 005-91836 25845935 34 59391 1 1
2025-04-17 8-K 8-K 1.01,2.02,5.02,7.01,9.01 0001193125-25-083523 001-39661 25844351 34 299763 1 1
2025-04-03 DEFA14A DEFA14A 0001193125-25-072426 001-39661 25810391 34 23044
2025-04-01 DEFA14A DEFA14A 0001193125-25-069935 001-39661 25796955 34 27021
2025-04-01 8-K 8-K 8.01 0001193125-25-069932 001-39661 25796952 34 158021 1 1
2025-03-26 DEFA14A DEFA14A 0001193125-25-064180 001-39661 25774298 34 27231
2025-03-26 DFAN14A dfan14a09076068_03262025.htm 0000921895-25-000883 001-39661 25772281 34 38218
2025-03-24 DEFA14A DEFA14A 0001193125-25-060808 001-39661 25762157 34 36372
2025-03-24 8-K 8-K 8.01,9.01 0001193125-25-060794 001-39661 25762143 34 171685 1 1
2025-03-21 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000921895-25-000843 005-91836 25759653 34 98803 1 1
2025-03-06 10-K 10-K 0000950170-25-034808 001-39661 25715954 34 14616497 1 1
2025-03-06 8-K 8-K 2.02,9.01 0001193125-25-048426 001-39661 25715455 34 217851 1 1
2025-03-04 SCHEDULE 13D xslSCHEDULE_13D_X01/primary_doc.xml 0000921895-25-000684 005-91836 25701815 34 105625 1 1
2025-02-24 4 4 0000950170-25-025901 5257
2025-02-24 3 3 0000950170-25-025892 20200
2025-02-24 8-K 8-K 5.02 0001193125-25-032826 001-39661 25654312 34 145811 1 1
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000935836-25-000162 005-91836 25625877 34 15882
2025-02-04 4 4 0000950170-25-013853 14528
2025-02-04 4 4 0000950170-25-013852 15075
2025-02-04 4 4 0000950170-25-013850 14339
2025-02-04 4 4 0000950170-25-013849 14609
2025-02-04 4 4 0000950170-25-013846 15048
2025-02-04 4 4 0000950170-25-013844 14306
2025-01-17 4/A 4/A 0000950170-25-006589 7329
2025-01-17 4 4 0000950170-25-006489 6817
2025-01-14 8-K 8-K 2.02,9.01 0001193125-25-005424 001-39661 25527365 34 178623 1 1
2024-12-16 SCHEDULE 13D xslSCHEDULE_13D_X01/primary_doc.xml 0001373604-24-000114 005-91836 241550366 34 15145
2024-12-12 4 4 0000950170-24-135930 4919
2024-12-10 144 xsl144X01/primary_doc.xml 0001968582-24-001157 001-39661 241539414 33 5900
2024-11-19 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-11-19 16:00:00 9999999995-24-003516 333-283073 241478077 33 1765
2024-11-15 CORRESP filename1.htm 0001193125-24-259812 6875
2024-11-14 SC 13G/A avir13ga3.htm 0000935836-24-000713 005-91836 241466290 34 47291
2024-11-14 UPLOAD filename1.pdf 0000000000-24-012648 333-283073 40155
2024-11-12 SC 13G/A filing.txt 0000315066-24-002676 005-91836 241444460 34 8059
2024-11-07 S-3 FORM S-3 0001193125-24-253272 333-283073 241436856 33 654276
2024-11-07 10-Q 10-Q 0000950170-24-123447 001-39661 241436629 34 7226198 1 1
2024-11-07 8-K 8-K 2.02,9.01 0001193125-24-253143 001-39661 241436262 34 215002 1 1
2024-09-19 4 4 0000950170-24-108233 9858
2024-09-19 144 xsl144X01/primary_doc.xml 0001973141-24-000465 001-39661 241310661 33 5951
2024-09-18 144 xsl144X01/primary_doc.xml 0001973141-24-000462 001-39661 241307544 33 5322
2024-09-17 144 xsl144X01/primary_doc.xml 0001973141-24-000460 001-39661 241304619 33 4690
2024-08-07 10-Q 10-Q 0000950170-24-092914 001-39661 241184534 34 7206120 1 1
2024-08-07 8-K 8-K 2.02,9.01 0001193125-24-195895 001-39661 241183993 34 220248 1 1
2024-06-21 4 4 0000950170-24-076400 7866
2024-06-21 4 4 0000950170-24-076394 7826
2024-06-21 4 4 0000950170-24-076388 7841
2024-06-21 4 4 0000950170-24-076381 7832
2024-06-21 4 4 0000950170-24-076379 9574
2024-06-21 4 4 0000950170-24-076363 7841
2024-06-21 8-K 8-K 5.07 0001193125-24-165886 001-39661 241061423 34 153511 1 1
2024-06-20 144 xsl144X01/primary_doc.xml 0001972362-24-000924 001-39661 241057608 33 4244
2024-06-18 4 4 0000950170-24-074989 6760
2024-06-18 4 4 0000950170-24-074988 6750
2024-06-18 4 4 0000950170-24-074987 6745
2024-06-18 4 4 0000950170-24-074986 6747
2024-06-18 4 4 0000950170-24-074985 6784
2024-06-18 4 4 0000950170-24-074984 6759
2024-06-07 4 4 0000950170-24-070965 5117
2024-06-05 144 xsl144X01/primary_doc.xml 0001973141-24-000291 001-39661 241021950 33 4686
2024-06-04 DEFA14A DEFA14A 0000950170-24-068683 001-39661 241018202 34 75970
2024-05-14 10-Q 10-Q 0000950170-24-059699 001-39661 24945203 34 6557368 1 1
2024-05-14 8-K 8-K 2.02,9.01 0001193125-24-138249 001-39661 24944581 34 209504 1 1
2024-04-26 DEFA14A DEFA14A 0000950170-24-049220 001-39661 24884418 34 1167501
2024-04-26 DEF 14A DEF 14A 0000950170-24-049178 001-39661 24884121 34 5786872 1 1
2024-02-28 10-K 10-K 0000950170-24-022226 001-39661 24696550 34 12780308 1 1
2024-02-28 8-K 8-K 2.02,9.01 0001193125-24-050724 001-39661 24695682 34 220548 1 1
2024-02-14 SC 13G/A avir13ga.htm 0000935836-24-000226 005-91836 24642814 34 47288
2024-02-14 SC 13G/A avir13ga.htm 0000935836-24-000207 005-91836 24642393 34 47288
2024-02-14 SC 13G/A avir13ga.htm 0000935836-24-000228 005-91836 24641587 34 45903
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-020352 005-91836 24627412 34 13051
2024-02-13 SC 13G/A SC 13G/A 0001193125-24-033799 005-91836 24626502 34 58415
2024-02-09 SC 13G/A filing.txt 0000315066-24-000968 005-91836 24611337 34 8086
2024-02-07 SC 13G/A avir13g.htm 0001616824-24-000017 005-91836 24602422 34 83456
2024-02-07 SC 13G avir13g.htm 0001616824-24-000015 005-91836 24602396 34 83448
2024-02-02 4 4 0000950170-24-010973 10941
2024-02-02 4 4 0000950170-24-010972 11435
2024-02-02 4 4 0000950170-24-010970 10734
2024-02-02 4 4 0000950170-24-010969 10701
2024-02-02 4 4 0000950170-24-010968 11470
2024-02-02 4 4 0000950170-24-010967 10922
2024-02-01 144 xsl144X01/primary_doc.xml 0000950170-24-009804 001-39661 24587106 33 4358
2024-02-01 144 xsl144X01/primary_doc.xml 0000950170-24-009803 001-39661 24587105 33 4389
2024-02-01 144 xsl144X01/primary_doc.xml 0000950170-24-009802 001-39661 24587104 33 4386
2024-02-01 144 xsl144X01/primary_doc.xml 0000950170-24-009801 001-39661 24587102 33 4376
2024-02-01 144 xsl144X01/primary_doc.xml 0000950170-24-009800 001-39661 24587101 33 4391
2024-02-01 144 xsl144X01/primary_doc.xml 0000950170-24-009799 001-39661 24587100 33 4367
2024-01-24 SC 13G/A us04683r1068_012324.txt 0001086364-24-002027 005-91836 24554588 34 13510
2023-11-28 SC 13D/A AMENDMENT NO. 1 0001214659-23-015585 005-91836 231441769 34 92800
2023-11-08 10-Q 10-Q 0000950170-23-061213 001-39661 231388640 34 8022786 1 1
2023-11-08 8-K 8-K 2.02,9.01 0001193125-23-273532 001-39661 231388081 34 216844 1 1
2023-11-07 SC 13G/A us04683r1068_110623.txt 0001306550-23-010280 005-91836 231383348 34 13419
2023-10-02 SC 13G avir13g.htm 0001616824-23-000007 005-91836 231298475 34 60254
2023-09-11 SC 13G/A filing.txt 0000315066-23-002589 005-91836 231246754 34 7978
2023-08-08 10-Q 10-Q 0000950170-23-039920 001-39661 231152176 34 8945143 1 1
2023-08-08 8-K 8-K 2.02,9.01 0001193125-23-206247 001-39661 231151697 34 220597 1 1
2023-06-21 8-K 8-K 5.03,5.07,9.01 0001193125-23-171257 001-39661 231030687 34 693037 1 1
2023-06-21 4 FORM 4 SUBMISSION 0000899243-23-016129 8179
2023-06-21 4 FORM 4 SUBMISSION 0000899243-23-016128 8167
2023-06-21 4 FORM 4 SUBMISSION 0000899243-23-016131 8164
2023-06-21 4 FORM 4 SUBMISSION 0000899243-23-016126 8170
2023-06-21 4 FORM 4 SUBMISSION 0000899243-23-016130 8179
2023-06-21 4 FORM 4 SUBMISSION 0000899243-23-016127 8204
2023-06-12 DEFA14A DEFA14A 0000950170-23-027367 001-39661 231007156 34 104307
2023-05-25 DEFA14A DEFA14A 0000950170-23-024297 001-39661 23962060 34 103380
2023-05-22 SC 13D z519230sc13d.htm 0001214659-23-007616 005-91836 23942601 34 124062
2023-05-08 10-Q 10-Q 0000950170-23-018869 001-39661 23898381 34 7973801 1 1
2023-05-08 8-K 8-K 2.02,9.01 0001193125-23-138257 001-39661 23897966 34 205658 1 1
2023-04-28 ARS ARS 0000950170-23-015921 001-39661 23867653 34 1933349
2023-04-28 DEFA14A DEFA14A 0000950170-23-015810 001-39661 23866280 34 1159476
2023-04-28 DEF 14A DEF 14A 0000950170-23-015773 001-39661 23866007 34 9088751 1 1
2023-02-28 10-K 10-K 0000950170-23-005186 001-39661 23686769 34 15885041 1 1
2023-02-28 8-K 8-K 2.02,9.01 0001193125-23-053843 001-39661 23685396 34 224725 1 1
2023-02-10 SC 13G/A SC 13G/A 0001193125-23-032602 005-91836 23612077 34 58101
2023-02-10 SC 13G/A avia13ga.htm 0000935836-23-000099 005-91836 23610224 34 47198
2023-02-09 SC 13G/A SCHEDULE 13G/A 0001104659-23-015377 005-91836 23602470 34 12971
2023-02-09 SC 13G/A filing.txt 0000315066-23-001421 005-91836 23601272 34 8177
2023-02-02 4 FORM 4 SUBMISSION 0000899243-23-003629 7918
2023-02-02 4 FORM 4 SUBMISSION 0000899243-23-003621 7951
2023-02-02 4 FORM 4 SUBMISSION 0000899243-23-003615 7947
2023-02-02 4 FORM 4 SUBMISSION 0000899243-23-003607 7938
2023-02-02 4 FORM 4 SUBMISSION 0000899243-23-003604 7943
2023-02-02 4 FORM 4 SUBMISSION 0000899243-23-003600 7936
2023-01-24 SC 13G/A us04683r1068_012423.txt 0001306550-23-003083 005-91836 23547505 34 13343
2022-11-15 4 FORM 4 SUBMISSION 0000899243-22-035942 6895
2022-11-07 10-Q 10-Q 0000950170-22-022699 001-39661 221366295 34 7590678 1 1
2022-11-07 8-K 8-K 2.02,9.01 0001193125-22-279097 001-39661 221365662 34 209194 1 1
2022-08-08 10-Q 10-Q 0000950170-22-015570 001-39661 221144871 34 6185654 1 1
2022-08-08 8-K 8-K 2.02,9.01 0001193125-22-214871 001-39661 221144466 34 210205 1 1
2022-06-21 4 FORM 4 SUBMISSION 0000899243-22-023505 5479
2022-06-21 4 FORM 4 SUBMISSION 0000899243-22-023504 5439
2022-06-21 4 FORM 4 SUBMISSION 0000899243-22-023502 5454
2022-06-21 4 FORM 4 SUBMISSION 0000899243-22-023501 5454
2022-06-21 4 FORM 4 SUBMISSION 0000899243-22-023498 5445
2022-06-21 4 FORM 4 SUBMISSION 0000899243-22-023496 5442
2022-06-21 8-K 8-K 5.07 0001193125-22-177774 001-39661 221029047 34 152042 1 1
2022-05-12 EFFECT xslEFFECTX01/primary_doc.xml POS AM,0001193125-22-146286,2022-05-12 9999999995-22-001427 333-261344 22920041 33 1728
2022-05-10 POS AM POS AM 0001193125-22-146286 333-261344 22909666 33 70279
2022-05-10 10-Q 10-Q 0000950170-22-008732 001-39661 22907447 34 5120004 1 1
2022-05-10 8-K 8-K 2.02,9.01 0001193125-22-145634 001-39661 22907264 34 237245 1 1
2022-04-29 DEFA14A DEFA14A 0001193125-22-134271 001-39661 22877533 34 482268
2022-04-29 DEF 14A DEF 14A 0001193125-22-134263 001-39661 22877477 34 1899458
2022-03-01 POS AM POS AM 0001193125-22-058650 333-261344 22692462 33 437891
2022-02-28 10-K 10-K 0001564590-22-007672 001-39661 22691232 34 17445742 1 1
2022-02-28 POSASR POSASR 0001193125-22-058027 333-261344 22690333 33 439022
2022-02-28 8-K 8-K 2.02,9.01 0001193125-22-057911 001-39661 22689588 34 222748 1 1
2022-02-16 SC 13G/A SC 13G/A 0001104659-22-024235 005-91836 22643482 34 73169
2022-02-14 SC 13G/A ATEA PHARMACEUTICALS, INC. 0001104659-22-022762 005-91836 22631941 34 82596
2022-02-14 SC 13G/A schedule13g.htm 0000929638-22-000477 005-91836 22630162 34 152378
2022-02-10 SC 13G/A SC 13G/A 0001193125-22-034452 005-91836 22614107 34 57184
2022-02-09 SC 13G SCHEDULE 13G 0001104659-22-016552 005-91836 22606479 34 12930
2022-02-09 SC 13G/A filing.txt 0000315066-22-000787 005-91836 22604091 34 8796
2022-02-04 SC 13G us04683r1068_020422.txt 0000834237-22-007341 005-91836 22593615 34 13328
2022-02-02 4 FORM 4 SUBMISSION 0000899243-22-004183 5381
2022-02-02 4 FORM 4 SUBMISSION 0000899243-22-004186 5400
2022-02-02 4 FORM 4 SUBMISSION 0000899243-22-004185 5421
2022-02-02 4 FORM 4 SUBMISSION 0000899243-22-004182 5420
2022-02-02 4 FORM 4 SUBMISSION 0000899243-22-004184 5346
2022-02-02 4 FORM 4 SUBMISSION 0000899243-22-004181 5407
2022-01-10 8-K 8-K 7.01,9.01 0001193125-22-005119 001-39661 22519782 34 13093791 1 1
2021-12-21 4 FORM 4 SUBMISSION 0000899243-21-049313 5018
2021-12-10 SC 13G ateapharm13g.htm 0000935836-21-000685 005-91836 211486168 34 45428
2021-11-26 8-K 8-K 7.01 0001193125-21-341283 001-39661 211452122 34 143581 1 1
2021-11-24 S-3ASR S-3ASR 0001193125-21-340320 333-261344 211446470 33 881526
2021-11-16 8-K 8-K 1.02 0001193125-21-331369 001-39661 211417311 34 145057 1 1
2021-11-12 10-Q 10-Q 0001564590-21-056513 001-39661 211399948 34 5797393 1 1
2021-11-12 8-K 8-K 2.02,9.01 0001193125-21-327268 001-39661 211399450 34 223899 1 1
2021-09-24 SC 13D/A SC 13D/A 0001193125-21-282487 005-91836 211278229 34 66899
2021-09-03 SC 13D/A SC 13D/A 0001193125-21-265615 005-91836 211237246 34 65820
2021-08-12 10-Q 10-Q 0001564590-21-044060 001-39661 211168793 34 6957707 1 1
2021-08-12 8-K 8-K 2.02,9.01 0001193125-21-244683 001-39661 211167667 34 96048
2021-07-23 8-K 8-K 1.01,2.03,9.01 0001193125-21-223025 001-39661 211111040 34 86062
2021-06-21 4 FORM 4 SUBMISSION 0000899243-21-025049 5437
2021-06-21 4 FORM 4 SUBMISSION 0000899243-21-025047 5440
2021-06-21 4 FORM 4 SUBMISSION 0000899243-21-025045 5474
2021-06-21 4 FORM 4 SUBMISSION 0000899243-21-025044 5434
2021-06-21 4 FORM 4 SUBMISSION 0000899243-21-025037 5449
2021-06-21 8-K 8-K 5.07 0001193125-21-195034 001-39661 211030522 34 21272
2021-05-20 4 FORM 4 SUBMISSION 0000899243-21-020247 5277
2021-05-20 3 FORM 3 SUBMISSION 0000899243-21-020241 6961
2021-05-20 8-K 8-K 5.02,9.01 0001193125-21-167921 001-39661 21945304 34 54188
2021-05-20 DEFA14A DEFA14A 0001193125-21-167778 001-39661 21944584 34 28585
2021-05-13 10-Q 10-Q 0001564590-21-027644 001-39661 21920827 34 4019161 1
2021-05-13 8-K 8-K 2.02,9.01 0001193125-21-160492 001-39661 21919713 34 67979
2021-04-29 DEFA14A DEFA14A 0001193125-21-140416 001-39661 21870621 34 552677
2021-04-29 DEF 14A DEF 14A 0001193125-21-140382 001-39661 21870516 34 820146
2021-04-19 8-K 8-K 5.02 0001193125-21-120430 001-39661 21833303 34 16695
2021-04-07 SC 13G/A SC 13G/A 0001104659-21-047577 005-91836 21812487 34 83461
2021-03-30 10-K 10-K 0001564590-21-016724 001-39661 21787961 34 9796241 1
2021-03-10 SC 13G/A filing.txt 0000315066-21-001424 005-91836 21728492 34 8446
2021-02-16 SC 13G SC 13G 0001104659-21-024251 005-91836 21639684 34 72073
2021-02-16 SC 13G SCHEDULE 13G 0001104659-21-024052 005-91836 21638800 34 88248
2021-02-16 SC 13G/A schedule13g.htm 0000929638-21-000379 005-91836 21637190 34 152706
2021-02-10 SC 13G SC 13G 0001193125-21-036341 005-91836 21614340 34 66277
2021-02-08 SC 13G filing.txt 0000315066-21-000815 005-91836 21599319 34 8441
2021-02-01 4 FORM 4 SUBMISSION 0000899243-21-003873 5356
2021-02-01 4 FORM 4 SUBMISSION 0000899243-21-003872 5352
2021-02-01 4 FORM 4 SUBMISSION 0000899243-21-003869 5347
2021-02-01 4 FORM 4 SUBMISSION 0000899243-21-003868 5345
2021-02-01 4 FORM 4 SUBMISSION 0000899243-21-003867 5360
2021-02-01 4 FORM 4 SUBMISSION 0000899243-21-003866 5357
2020-12-10 10-Q 10-Q 0001564590-20-056724 001-39661 201380710 34 6053498 1
2020-11-13 SC 13G schedule13g.htm 0000929638-20-001091 005-91836 201311373 34 173782
2020-11-12 SC 13D SC 13D 0001193125-20-291677 005-91836 201306894 34 124321
2020-11-05 8-K 8-K 5.03,9.01 0001193125-20-286850 001-39661 201290825 34 274908
2020-11-05 4 FORM 4 0001567619-20-018747 26026
2020-11-04 4 FORM 4 SUBMISSION 0000899243-20-030382 23813
2020-11-03 4 FORM 4 SUBMISSION 0000899243-20-030340 12858
2020-11-03 4 FORM 4 SUBMISSION 0000899243-20-030332 9744
2020-11-03 4 FORM 4 SUBMISSION 0000899243-20-030331 17231
2020-11-03 4 FORM 4 SUBMISSION 0000899243-20-030330 9237
2020-11-03 4 FORM 4 SUBMISSION 0000899243-20-030329 7374
2020-11-03 4 FORM 4 SUBMISSION 0000899243-20-030324 11355
2020-11-03 4 FORM 4 SUBMISSION 0000899243-20-030323 7431
2020-10-30 4 FORM 4 SUBMISSION 0000899243-20-029960 5275
2020-10-30 4 FORM 4 SUBMISSION 0000899243-20-029959 5238
2020-10-30 4 FORM 4 SUBMISSION 0000899243-20-029956 5244
2020-10-30 4 FORM 4 SUBMISSION 0000899243-20-029954 5247
2020-10-30 4 FORM 4 SUBMISSION 0000899243-20-029953 5290
2020-10-30 4 FORM 4 SUBMISSION 0000899243-20-029951 5244
2020-10-30 S-8 S-8 0001193125-20-282778 333-249780 201278371 33 132384
2020-10-30 4 FORM 4 SUBMISSION 0000899243-20-029945 5238
2020-10-30 424B4 424B4 0001193125-20-282645 333-249404 201277790 33 4233529
2020-10-29 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2020-10-29 16:00:00 9999999995-20-003030 333-249404 201274575 33 1712
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029797 12346
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029796 7255
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029795 9624
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029793 10111
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029794 12329
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029781 14386
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029779 7222
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029778 10114
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029777 11147
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029776 22689
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029775 15926
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029774 8532
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029773 11245
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029772 8565
2020-10-29 3 FORM 3 SUBMISSION 0000899243-20-029765 6509
2020-10-29 3 FORM 3 0001567619-20-018348 17515
2020-10-29 S-1MEF S-1MEF 0001193125-20-281196 333-249736 201273734 33 44760
2020-10-29 CORRESP filename1.htm 0001193125-20-280670 41089
2020-10-28 CERT 8A CERT 0001354457-20-000645 001-39661 201266455 34 488137
2020-10-27 SEC STAFF LETTER filename1.pdf 9999999997-20-005162 274587
2020-10-27 CORRESP filename1.htm 0001193125-20-278377 13488
2020-10-27 CORRESP filename1.htm 0001193125-20-278374 7472
2020-10-27 UPLOAD filename1.pdf 0000000000-20-010154 42413
2020-10-26 S-1/A AMENDMENT 2 TO FORM S-1 0001193125-20-275997 333-249404 201258971 33 5300053
2020-10-26 8-A12B 8-A12B 0001193125-20-275982 001-39661 201258957 34 12646
2020-10-23 SEC STAFF LETTER filename1.pdf 9999999997-20-005123 276764
2020-10-23 S-1/A AMENDMENT 1 TO FORM S-1 0001193125-20-274635 333-249404 201255906 33 5355937
2020-10-09 S-1 S-1 0001193125-20-267199 333-249404 201233224 33 5892744
2020-08-07 DRSLTR filename1.htm 0000950123-20-007961 47448
2020-08-07 DRS/A filename1.htm 0000950123-20-007958 377-03231 201086570 33 4269022
2020-07-16 UPLOAD filename1.pdf 0000000000-20-006512 58271
2020-06-19 DRS filename1.htm 0000950123-20-006302 377-03231 20974093 33 4896607
2020-05-29 D xslFormDX01/primary_doc.xml 06b 0001567619-20-011337 021-367951 20927396 33 12043
2018-07-16 D xslFormDX01/primary_doc.xml 06b 0001140361-18-032512 021-316941 18954220 33 11998
2016-09-13 D xslFormDX01/primary_doc.xml 06b 0001140361-16-079687 021-270551 161883297 33 11090
2014-09-17 D/A xslFormDX01/primary_doc.xml 06b 0001140361-14-035805 021-207797 141107035 33 10696
2014-05-21 D/A xslFormDX01/primary_doc.xml 06b 0001140361-14-022477 021-207797 14860767 33 10593
2013-12-11 D xslFormDX01/primary_doc.xml 06b 0001140361-13-045616 021-207797 131270503 33 10509

Latest XBRL company facts

One latest value per concept from companyfacts (234 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 80.30M 2026-11-06 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
dei EntityPublicFloat Entity Public Float USD 262.60M 2025-06-30 2025 FY 10-K 2026-03-05 0001193125-26-094159
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 1.64M 2025-01-01 2025-12-31 DEF 14A 2026-04-27 0001193125-26-182293
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.57M 2025-01-01 2025-12-31 DEF 14A 2026-04-27 0001193125-26-182293
ecd PeerGroupTotalShareholderRtnAmt PeerGroupTotalShareholderRtnAmt USD 124.75 2025-01-01 2025-12-31 DEF 14A 2026-04-27 0001193125-26-182293
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 3.60M 2025-01-01 2025-12-31 DEF 14A 2026-04-27 0001193125-26-182293
ecd PeoTotalCompAmt PeoTotalCompAmt USD 3.40M 2025-01-01 2025-12-31 DEF 14A 2026-04-27 0001193125-26-182293
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 8.54 2025-01-01 2025-12-31 DEF 14A 2026-04-27 0001193125-26-182293
srt StockRepurchaseProgramAuthorizedAmount1 StockRepurchaseProgramAuthorizedAmount1 USD 25.00M 2025-04-30 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 4.84M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 4.51M 2022-09-30 2022 Q3 10-Q 2022-11-07 0000950170-22-022699
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 1.51M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AccruedIncomeTaxesCurrent Accrued Income Taxes, Current USD 99,000 2022-12-31 2023 FY 10-K 2024-02-28 0000950170-24-022226
us-gaap AccruedIncomeTaxesNoncurrent Accrued Income Taxes, Noncurrent USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 19.97M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 1.52M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -73,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 808.78M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 3.47M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD 657,000 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 10.58M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD -11.10M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061213
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 13.18M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-10 0000950170-22-008732
us-gaap Assets Assets USD 200.71M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AssetsCurrent Assets, Current USD 200.27M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 185.99M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 1,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 74,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 93.35M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value USD 91.28M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value USD 2.00M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 93.28M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 93.28M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-sale, Noncurrent USD 0 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277815
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 702,000 2022-01-01 2022-03-31 2023 Q1 10-Q 2023-05-08 0000950170-23-018869
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 97.92M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap CashAndCashEquivalentsFairValueDisclosure Cash and Cash Equivalents, Fair Value Disclosure USD 657.92M 2022-06-30 2022 Q2 10-Q 2022-08-08 0000950170-22-015570
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 191.20M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 97.92M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 2.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 36.04M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 300.00M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 80.30M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 80.30M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap CommonStockValue Common Stock, Value, Issued USD 80,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -110.78M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 283.23M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 48.96M 2020-09-30 2020 Q3 10-Q 2020-12-10 0001564590-20-056724
us-gaap CurrentFederalStateAndLocalTaxExpenseBenefit Current Federal, State and Local, Tax Expense (Benefit) USD -6.16M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD -6.21M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD -3.71M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-07 0000950170-22-022699
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 45,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously Recorded USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 16.16M 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123447
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss USD 74,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Security 21 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DeferredFederalStateAndLocalTaxExpenseBenefit Deferred Federal, State and Local, Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD -6.36M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 301.37M 2020-12-31 2021 FY 10-K 2022-02-28 0001564590-22-007672
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 162.33M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 14.30M 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 56.41M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 266,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 18.94M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 23.93M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 162.33M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DeferredTaxLiabilitiesPrepaidExpenses Deferred Tax Liabilities, Prepaid Expenses USD 477,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 689,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 312,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -1.38 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.51 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-30 0001564590-21-016724
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -1.38 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0.037 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.222 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.015 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent pure 0.034 2022-01-01 2022-12-31 2023 FY 10-K 2024-02-28 0000950170-24-022226
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Percent pure 0.039 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsForeign Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent pure 0.061 2021-01-01 2021-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.028 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 5.22M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 128.04M 2021-12-31 2021 FY 10-K 2022-02-28 0001564590-22-007672
us-gaap FederalIncomeTaxExpenseBenefitContinuingOperations Federal Income Tax Expense (Benefit), Continuing Operations USD -6.21M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations USD -6.16M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 20.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -110.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 112,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 36.56M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -34.55M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 21,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 2.47M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 144,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 150,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap IncomeTaxReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Amount USD -6.36M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 4.61M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -8.10M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 4.51M 2022-01-01 2022-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061213
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD -6.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap IncreaseDecreaseInContractWithCustomerAsset Increase (Decrease) in Contract with Customer, Asset USD 5.82M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD -301.37M 2021-01-01 2021-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -157,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD -3.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -92,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap InterestAndOtherIncome Interest and Other Income USD 6.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap LeaseCost Lease, Cost USD 708,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate pure 0.031 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 213,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 855,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 855,000 2021-12-31 2021 FY 10-K 2022-02-28 0001564590-22-007672
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 855,000 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 855,000 2023-12-31 2023 FY 10-K 2024-02-28 0000950170-24-022226
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 855,000 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034808
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 209,000 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277815
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 12,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap Liabilities Liabilities USD 39.78M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 200.71M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap LiabilitiesCurrent Liabilities, Current USD 25.02M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 452,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 114.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -112.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -110.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap OperatingExpenses Operating Expenses USD 117.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -117.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap OperatingLeaseCost Operating Lease, Cost USD 485,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 646,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 843,000 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 213,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 161,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 540,000 2020-12-31 2020 FY 10-K 2021-03-30 0001564590-21-016724
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 340,000 2020-12-31 2020 FY 10-K 2021-03-30 0001564590-21-016724
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 200,000 2020-09-30 2020 Q3 10-Q 2020-12-10 0001564590-20-056724
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 200,000 2020-12-31 2020 FY 10-K 2021-03-30 0001564590-21-016724
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 85,000 2020-09-30 2020 Q3 10-Q 2020-12-10 0001564590-20-056724
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 132,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD 23,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -247,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 5.93M 2021-12-31 2021 FY 10-K 2022-02-28 0001564590-22-007672
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 25.52M 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 1.13M 2020-01-01 2020-09-30 2021 Q3 10-Q 2021-11-12 0001564590-21-056513
us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment, Tax Withholding, Share-based Payment Arrangement USD 746,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 120.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 1.94M 2022-01-01 2022-12-31 2023 FY 10-K 2024-02-28 0000950170-24-022226
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 9.07M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 317.61M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 1.47M 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-28 0001564590-22-007672
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 214.12M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 234.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Proceeds from Sale of Debt Securities, Available-for-sale USD 0 2022-07-01 2022-09-30 2022 Q3 10-Q 2022-11-07 0000950170-22-022699
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 951,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 247,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -110.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 1.98M 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 145,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 96.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap RestrictedCash Restricted Cash USD 198,000 2023-06-30 2024 Q2 10-Q 2024-08-07 0000950170-24-092914
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 198,000 2022-12-31 2023 FY 10-K 2024-02-28 0000950170-24-022226
us-gaap RestrictedStockValueSharesIssuedNetOfTaxWithholdings Restricted Stock, Value, Shares Issued Net of Tax Withholdings USD -746,000 2026-01-01 2026-03-31 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -633.10M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 351.37M 2021-01-01 2021-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 2.94M 2022-01-01 2022-12-31 2023 FY 10-K 2024-02-28 0000950170-24-022226
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 10.58M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.8 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.917 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.8 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.044 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.006 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.003 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 23.50M 2021-12-31 2021 FY 10-K 2022-02-28 0001564590-22-007672
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 4.56M 2021-12-31 2021 FY 10-K 2022-02-28 0001564590-22-007672
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 11.33 2021-12-31 2021 FY 10-K 2022-02-28 0001564590-22-007672
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 2.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 57.97 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 611,325 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-07 0000950170-22-022699
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures shares 2.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 3.74M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-07 0000950170-22-022699
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 2.2 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 24.19M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 21.79M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 6.37 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 17.58M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number shares 17.04M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price USD/shares 7.08 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 24.19M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 21.79M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 6.37 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 1.36 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 4.29 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap StateAndLocalIncomeTaxExpenseBenefitContinuingOperations State and Local Income Tax Expense (Benefit), Continuing Operations USD 45,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 175.68M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 694,349 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 283.23M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 115,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 317.61M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross USD 117,000 2024-07-01 2024-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277815
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 80,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares shares 7.67M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap StockRepurchasedDuringPeriodValue Stock Repurchased During Period, Value USD 11.43M 2025-07-01 2025-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Stock Repurchase Program, Remaining Authorized Repurchase Amount USD 11.09M 2025-06-30 2025 Q2 10-Q 2025-08-07 0000950170-25-105123
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 69.11M 2019-12-31 2020 FY 10-K 2021-03-30 0001564590-21-016724
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 178.11M 2020-09-30 2020 Q3 10-Q 2020-12-10 0001564590-20-056724
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0.001 2020-12-31 2020 FY 10-K 2021-03-30 0001564590-21-016724
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 0 2020-12-31 2020 FY 10-K 2021-03-30 0001564590-21-016724
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 0 2020-12-31 2020 FY 10-K 2021-03-30 0001564590-21-016724
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2020-12-31 2020 FY 10-K 2021-03-30 0001564590-21-016724
us-gaap TemporaryEquityValueExcludingAdditionalPaidInCapital Temporary Equity, Par Value USD 175.75M 2020-09-30 2020 Q3 10-Q 2020-12-10 0001564590-20-056724
us-gaap UnbilledReceivablesCurrent Unbilled Receivables, Current USD 5.82M 2020-12-31 2021 FY 10-K 2022-02-28 0001564590-22-007672
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions USD 943,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-30 0001564590-21-016724
us-gaap UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations USD 5.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 45.11M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap VariableLeaseCost Variable Lease, Cost USD 62,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-05 0001193125-26-094159
us-gaap WeightedAverageNumberDilutedSharesOutstandingAdjustment Weighted Average Number Diluted Shares Outstanding Adjustment shares 5.43M 2021-01-01 2021-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005186
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 79.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 21.59M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-30 0001564590-21-016724
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 79.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453807

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →